• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实用指南:使用贝叶斯方法的适应性无缝二期/三期临床试验

Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.

机构信息

Warwick Medical School, The University of Warwick, Coventry, CV4 7AL, UK.

出版信息

Stat Med. 2012 Aug 30;31(19):2068-85. doi: 10.1002/sim.5326. Epub 2012 Mar 22.

DOI:10.1002/sim.5326
PMID:22437262
Abstract

Hommel (Biometrical Journal; 45:581-589) proposed a flexible testing procedure for seamless phase II/III clinical trials. Schmidli et al. (Statistics in Medicine; 26:4925-4938), Kimani et al. (Statistics in Medicine; 28:917-936) and Brannath et al. (Statistics in Medicine; 28:1445-1463) exploited the flexible testing of Hommel to propose adaptation in seamless phase II/III clinical trials that incorporate prior knowledge by using Bayesian methods. In this paper, we show that adaptation incorporating prior knowledge may lead to higher power. Other important issues to consider in such adaptive designs are the gain in power (or saving in patients) over traditional testing and how utility values used to make the adaptation may be used to stop a trial early. In contrast to the aforementioned authors, we discuss these issues in detail and propose a unified approach to address them so that implementing the aforementioned designs and proposing similar designs is clearer.

摘要

霍梅尔(Biometrical Journal;45:581-589)提出了一种用于无缝二期/三期临床试验的灵活测试程序。施密德利等人(Statistics in Medicine;26:4925-4938)、金马尼等人(Statistics in Medicine;28:917-936)和布兰纳特等人(Statistics in Medicine;28:1445-1463)利用霍梅尔的灵活测试方法,通过贝叶斯方法提出了在无缝二期/三期临床试验中利用先验知识进行适应性调整的方法。在本文中,我们表明,包含先验知识的适应性调整可能会导致更高的功效。在这种自适应设计中,还需要考虑其他重要问题,例如与传统测试相比,功效的提高(或患者人数的减少),以及用于进行适应性调整的效用值如何用于提前终止试验。与上述作者不同,我们详细讨论了这些问题,并提出了一种统一的方法来解决这些问题,以便更清楚地实现上述设计和提出类似的设计。

相似文献

1
Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.实用指南:使用贝叶斯方法的适应性无缝二期/三期临床试验
Stat Med. 2012 Aug 30;31(19):2068-85. doi: 10.1002/sim.5326. Epub 2012 Mar 22.
2
Group-sequential methods for adaptive seamless phase II/III clinical trials.用于适应性无缝II/III期临床试验的序贯分组方法。
J Biopharm Stat. 2011 Jul;21(4):787-801. doi: 10.1080/10543406.2011.551335.
3
A seamless phase II/III design with sample-size re-estimation.具有样本量重新估计的无缝II/III期设计。
J Biopharm Stat. 2009 Jul;19(4):595-609. doi: 10.1080/10543400902963193.
4
Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.在终点为直至某个指定时间点的生存情况的无缝II/III期试验中用于中期适应性调整的贝叶斯预测能力。
Stat Med. 2007 Nov 30;26(27):4925-38. doi: 10.1002/sim.2957.
5
A Bayesian-frequentist two-stage single-arm phase II clinical trial design.贝叶斯-频率派两阶段单臂二期临床试验设计。
Stat Med. 2012 Aug 30;31(19):2055-67. doi: 10.1002/sim.5330. Epub 2012 Mar 13.
6
Plan to be flexible: a commentary on adaptive designs.灵活规划:关于适应性设计的评论
Biom J. 2006 Aug;48(4):656-9; discussion 660-2. doi: 10.1002/bimj.200610241.
7
An adaptive design to bridge the gap between Phase 2b/3 microbicide effectiveness trials and evidence required for licensure.一种适应性设计,旨在弥合 2b/3 期微物杀菌剂有效性试验与获得许可所需证据之间的差距。
Clin Trials. 2012 Aug;9(4):377-84. doi: 10.1177/1740774512445512. Epub 2012 May 18.
8
Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: opportunities and limitations.中期进行假设选择的验证性无缝II/III期临床试验:机遇与局限
Biom J. 2006 Aug;48(4):650-5; discussion 660-2. doi: 10.1002/bimj.200610248.
9
Sample size determination for phase II clinical trials based on Bayesian decision theory.基于贝叶斯决策理论的II期临床试验样本量确定
Biometrics. 1998 Mar;54(1):279-94.
10
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.一种用于肿瘤学试验的适应性无缝II/III期设计,该设计使用相关生存终点进行亚组选择。
Pharm Stat. 2011 Jul-Aug;10(4):347-56. doi: 10.1002/pst.472. Epub 2010 Dec 8.

引用本文的文献

1
A Seamless Hybrid Phase II/III Design With Bayesian Interim Subgroup Selection.一种采用贝叶斯中期亚组选择的无缝混合II/III期设计。
Stat Med. 2025 Jun;44(13-14):e70144. doi: 10.1002/sim.70144.
2
Application of radiomics in lung immuno-oncology.放射组学在肺部免疫肿瘤学中的应用。
Precis Radiat Oncol. 2023 Apr 4;7(2):128-136. doi: 10.1002/pro6.1191. eCollection 2023 Jun.
3
Using dichotomized survival data to construct a prior distribution for a Bayesian seamless Phase II/III clinical trial.使用二分类生存数据为贝叶斯无缝 II/III 期临床试验构建先验分布。
Stat Methods Med Res. 2023 May;32(5):963-977. doi: 10.1177/09622802231160554. Epub 2023 Mar 15.
4
Adaptive designs in clinical trials: why use them, and how to run and report them.临床试验中的适应性设计:为何使用它们,以及如何实施和报告它们。
BMC Med. 2018 Feb 28;16(1):29. doi: 10.1186/s12916-018-1017-7.
5
The Burden of the "False-Negatives" in Clinical Development: Analyses of Current and Alternative Scenarios and Corrective Measures.临床开发中的“假阴性”负担:当前和替代方案分析及纠正措施。
Clin Transl Sci. 2017 Nov;10(6):470-479. doi: 10.1111/cts.12478. Epub 2017 Jul 4.
6
Estimation after subpopulation selection in adaptive seamless trials.适应性无缝试验中亚组选择后的估计
Stat Med. 2015 Aug 15;34(18):2581-601. doi: 10.1002/sim.6506. Epub 2015 Apr 22.